Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) Meeting Abstract
| Authors: | Sangro, B.; Chan, S. L.; Kelley, K.; Lau, G.; Kudo, M.; Sukeepaisarnjaroen, W.; De Toni, E.; Furuse, J.; Kang, Y. K.; Galle, P. R.; Rimassa, L.; Heurgué, A.; Tam, V. C.; Dao, T. V.; Thungappa, S. C.; Breder, V.; Ostapenko, Y.; Reig, M.; Makowsky, M.; Gupta, C.; Negro, A.; Abou-Alfa, G. |
| Abstract Title: | Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) |
| Meeting Title: | 36. Deutscher Krebskongress - Fortschritt gemeinsam gestalten |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 47 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Feb 21-24 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2024-02-01 |
| Start Page: | 69 |
| End Page: | 70 |
| Language: | English |
| ACCESSION: | WOS:001332646400161 |
| PROVIDER: | wos |
| DOI: | 10.1159/000535363 |
| Notes: | Meeting Abstract: 377 -- 'The 36th German Cancer Congress - Building Progress Together' -- Located in the section 'Gastrointestinal Cancer: other than colorectal' -- Source: Wos |
